Unless otherwise noted, the financial results and earnings guidance included below have been recast to reflect the continuing operations of Johnson & Johnson.

## **FINANCIAL RESULTS:**

		SIX MONTHS		
(\$ in Millions, except EPS)	2023	2022	% Change	
Reported Sales	\$42,413	\$40,055	5.9%	
Net Earnings	\$4,885	\$8,833	(44.7)%	
EPS (diluted)	\$1.86	\$3.31	(43.8)%	

	SIX MONTHS		
Non-GAAP* (\$ in Millions, except EP\$)	2023	2022	% Change
Operational Sales <sup>1,2</sup>			8.0%
Adjusted Operational Sales <sup>1,3</sup>			6.4%
Adjusted Net Earnings <sup>1,4</sup>	\$13,070	\$12,426	5.2%
Adjusted EPS (diluted) 1.4	\$4.97	\$4.66	6.7%

<sup>&</sup>lt;sup>1</sup> Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

Note: values may have been rounded

## **REGIONAL SALES RESULTS:**

SIX MONTHS	% Change					
(\$ in Millions)	2023	2022	Reported	Operational <sup>1,2</sup>	Currency	Adjusted Operational <sup>1,3</sup>
U.S.	\$22,439	\$20,367	10.2%	10.2	-	7.6
International	19,974	19,688	1.5	5.8	(4.3)	5.4
Worldwide	\$42,413	\$40,055	5.9%	8.0	(2.1)	6.4

<sup>&</sup>lt;sup>1</sup> Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

Note: values may have been rounded

## **SEGMENT SALES RESULTS:**

SIX MONTHS			% Change			
(\$ in Millions)	2023	2022	Reported	Operational <sup>1,2</sup>	Currency	Adjusted Operational <sup>1,3</sup>
Pharmaceutical	27,144	26,186	3.7	5.5	(1.8)	5.6
MedTech	15,269	13,869	10.1	12.8	(2.7)	8.1
Worldwide	\$42,413	\$40,055	5.9%	8.0	(2.1)	6.4

<sup>&</sup>lt;sup>1</sup> Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

Note: Values may have been rounded

<sup>&</sup>lt;sup>2</sup> Excludes the impact of translational currency

<sup>&</sup>lt;sup>3</sup> Excludes the net impact of acquisitions and divestitures and translational currency

<sup>&</sup>lt;sup>4</sup> Excludes intangible amortization expense and special items

<sup>&</sup>lt;sup>2</sup> Excludes the impact of translational currency

<sup>&</sup>lt;sup>3</sup> Excludes the net impact of acquisitions and divestitures and translational currency

<sup>&</sup>lt;sup>2</sup> Excludes the impact of translational currency

<sup>&</sup>lt;sup>3</sup> Excludes the net impact of acquisitions and divestitures and translational currency